Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.0409 | 0.515 | 0.5 |
Brugia malayi | Matrixin family protein | 0.0272 | 0.2556 | 0.2556 |
Wolbachia endosymbiont of Brugia malayi | extracellular metallopeptidase | 0.0325 | 0.3548 | 0.5 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.0137 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.0137 | 0 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.0272 | 0.2556 | 0.2556 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.0409 | 0.515 | 0.5 |
Brugia malayi | Hemopexin family protein | 0.016 | 0.0426 | 0.0426 |
Mycobacterium ulcerans | hydrolase | 0.0137 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.016 | 0.0426 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.025 | 0.213 | 0.213 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.025 | 0.213 | 1 |
Loa Loa (eye worm) | angiotensin-converting enzyme family protein | 0.0665 | 1 | 1 |
Onchocerca volvulus | Matrilysin homolog | 0.025 | 0.213 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 31 ug kg-1 | In vivo beta adrenergic blocking potency was determined by inhibition of tachycardia produced by isoproterenol (0.2 mg/kg iv) in cat preparation | ChEMBL. | 6128420 |
ED50 (functional) | = 31 ug kg-1 | In vivo beta adrenergic blocking potency was determined by inhibition of tachycardia produced by isoproterenol (0.2 mg/kg iv) in cat preparation | ChEMBL. | 6128420 |
Inhibition (functional) | = 0 % | In vivo beta adrenergic blocking potency was determined by inhibition of depressor response produced by isoproterenol (0.2 mg/kg iv) in cat preparation | ChEMBL. | 6128420 |
Inhibition (functional) | = 0 % | In vivo beta adrenergic blocking potency was determined by inhibition of depressor response produced by isoproterenol (0.2 mg/kg iv) in cat preparation | ChEMBL. | 6128420 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.